Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.
暂无分享,去创建一个
G. Bartsch | A. Barsoum | H. Rogatsch | R. Ramoner | M. Thurnher | C. Papesh | C. Zelle-Rieser | J. Coggin | L. Höltl | Hubert Gander | L. Höltl
[1] T. Di Pucchio,et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. , 2001, Blood.
[2] F. Marincola,et al. Cytokines and Immune Response in the Tumor Microenvironment , 2001, Journal of immunotherapy.
[3] S. Endres,et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. , 2001, Cancer research.
[4] F. Tanaka,et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] G. Bartsch,et al. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. , 2001, The Journal of urology.
[6] F. Zintl,et al. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Lanzavecchia,et al. Migration and Function of Antigen-Primed Nonpolarized T Lymphocytes in Vivo , 2001, The Journal of experimental medicine.
[8] G. Bartsch,et al. The disabled dendritic cell. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] Edgar G. Engleman,et al. Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.
[10] J. Mulé,et al. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. , 2001, Cancer research.
[11] M. Roncarolo,et al. Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.
[12] Y. Horiguchi,et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Peshwa,et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Jäger,et al. The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes , 2000, Cell.
[15] F. Sallusto,et al. Understanding dendritic cell and T‐lymphocyte traffic through the analysis of chemokine receptor expression , 2000, Immunological reviews.
[16] J. Buckner,et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] T. Di Pucchio,et al. Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.
[18] G. Bartsch,et al. Mature Dendritic Cells Induce T-Helper Type-1-Dominant Immune Responses in Patients with Metastatic Renal Cell Carcinoma , 2000, Urologia Internationalis.
[19] H. Rammensee,et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.
[20] J. Schlom,et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] H. Klocker,et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. , 1999, The Journal of urology.
[22] A. Enk,et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.
[23] R. Coleman,et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.
[24] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[25] M. Mbizvo,et al. Dendritic Cell-Based Immunotherapy of Renal Cell Carcinoma , 1998, Urologia Internationalis.
[26] G. Bartsch,et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer , 1998, The Lancet.
[27] A. Barsoum,et al. Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. , 1998, Immunology today.
[28] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[29] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[30] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[31] A. Enk,et al. Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.
[32] R. Figlin,et al. Renal cell carcinoma: recent progress and future directions. , 1997, Cancer research.
[33] H. Klocker,et al. Prostaglandin E2 and Tumor Necrosis Factor ␣ Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997 .
[34] Antonio Lanzavecchia,et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.
[35] F. Marshall,et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.
[36] G. Murphy,et al. Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.
[37] H. Klocker,et al. Human renal‐cell carcinoma tissue contains dendritic cells , 1996, International journal of cancer.
[38] H. Klocker,et al. Tumor‐infiltrating T lymphocytes from renal‐cell carcinoma express B7‐1 (CD80): T‐Cell expansion by T‐T cell co‐stimulation , 1995, International journal of cancer.
[39] C Danieli,et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.
[40] E. Jaffee,et al. Gene therapy: its potential applications in the treatment of renal-cell carcinoma. , 1995, Seminars in oncology.
[41] R. Steinman,et al. Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.
[42] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[43] H. Claésson,et al. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. , 1989, Journal of immunology.
[44] A. Belldegrun,et al. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.
[45] I TOEROE,et al. [ON THE LYMPH NODES]. , 1964, Verhandlungen der Anatomischen Gesellschaft.
[46] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.